Baseline characteristics of studies including portal vein thrombosis patients
| Reference . | Y . | Design . | Male/female . | Median age, y (range) . | Median follow-up, mo, (range) . | MPN criteria . | MPNs . | JAK2V617F . | Classification (PV/ET/MF/U/solitaryJAK2)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||||||||
| Hoekstra et al64 | 2011 | RC | 13/31 | 48 (18-79) | 70 (5-252) | WHO 2008 criteria | NA | NA | NA | NA | 14/12/7/11/0 |
| Rajani et al57 | 2010 | RC | 80/93 | 57 (15-94) | 30 (0-116) | Not specified, BM in majority of patients | 15/89 | 17 | NA | NA | 10/4/0/0/0§ |
| Orr et al56 | 2010 | RC | 14/21 | 43 (18-72) | 51 (10-300) | WHO 2001, BM if MPN was suspected | 6/35 | 17 | 16/35 | 46 | 2/3/1/1/9§ |
| Plessier et al11 | 2010 | RC | 50/52 | 48 (16-84) | 20 (0-75) | WHO 2001, BM in majority of patients | 17/102 | 17 | 14/82 | 17 | 3/11/3/2/2 |
| Xavier et al60 | 2009 | RC | 40/37 | 42 (17-74) | 51 (1-104) | WHO 2001, BM if MPN was suspected | 3/76 | 4 | 15/76 | 20 | 1/3/2/1/8 |
| Kiladjian et al20 | 2008 | RC | 77/60 | 42 (IQR 30-57) | 66 (range NA) | Not specified, BM in nearly all patients | 48/137 | 28 | 47/137 | 34 | 14/8/3/23/0 |
| Bayraktar et al10 | 2008 | RC | 9/16 | 45 (24-73)† | NA | WHO, BM if MPN was suspected | 6/25 | 24 | 6/25 | 24 | 3/2/1/0/5 |
| DeStefano et al63 | 2007 | RC | 27/31 | NA | 48 (24-108)‡ | PVSG 2000 | 8/58 | 14 | 24/58 | 41 | 4/5/0/0/15 |
| McMahon et al50 | 2007 | RC | 9/1 | NA | NA | Not specified | 0/10 | 0 | 1/10 | 10 | 0/0/0/0/1 |
| Colaizzo et al21 | 2007 | RC | 44/55 | 41 (10-85) | 41 (3-114) | WHO 2001 | 9/99 | 9 | 17/99 | 17 | 3/5/5/2/5§ |
| Primignani et al52 | 2006 | RC | 29/44 | 42 (13-66) | NA | WHO 2001, based on BM only | 31/55 | 56 | 26/73 | 36 | 5/14/5/9/0 |
| Kocher et al55 | 2005 | RC | 10/10 | 51 (17-83) | 21 (2-61) | Not specified, BM if MPN was suspected | 6/20 | 30 | NA | NA | 2/4/0/0/0 |
| Janssen et al2 | 2001 | RC | NA | NA | 3.9 (0.1-13.1)† | Not specified, BM if MPN was suspected | 22/82 | 27 | NA | NA | 12/2/5/2/0§ |
| Denninger et al6 | 2000 | RC | NA | NA | NA | Not specified, BM if MPN was suspected | 5/36 | 14 | NA | NA | 5/0/0/6/0 |
| Valla et al12 | 1988 | RC | 14/17 | NA | NA | Not specified, BM if MPN was suspected | 7/31 | 23 | NA | NA | 2/1/2/6/0 |
| Reference . | Y . | Design . | Male/female . | Median age, y (range) . | Median follow-up, mo, (range) . | MPN criteria . | MPNs . | JAK2V617F . | Classification (PV/ET/MF/U/solitaryJAK2)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||||||||
| Hoekstra et al64 | 2011 | RC | 13/31 | 48 (18-79) | 70 (5-252) | WHO 2008 criteria | NA | NA | NA | NA | 14/12/7/11/0 |
| Rajani et al57 | 2010 | RC | 80/93 | 57 (15-94) | 30 (0-116) | Not specified, BM in majority of patients | 15/89 | 17 | NA | NA | 10/4/0/0/0§ |
| Orr et al56 | 2010 | RC | 14/21 | 43 (18-72) | 51 (10-300) | WHO 2001, BM if MPN was suspected | 6/35 | 17 | 16/35 | 46 | 2/3/1/1/9§ |
| Plessier et al11 | 2010 | RC | 50/52 | 48 (16-84) | 20 (0-75) | WHO 2001, BM in majority of patients | 17/102 | 17 | 14/82 | 17 | 3/11/3/2/2 |
| Xavier et al60 | 2009 | RC | 40/37 | 42 (17-74) | 51 (1-104) | WHO 2001, BM if MPN was suspected | 3/76 | 4 | 15/76 | 20 | 1/3/2/1/8 |
| Kiladjian et al20 | 2008 | RC | 77/60 | 42 (IQR 30-57) | 66 (range NA) | Not specified, BM in nearly all patients | 48/137 | 28 | 47/137 | 34 | 14/8/3/23/0 |
| Bayraktar et al10 | 2008 | RC | 9/16 | 45 (24-73)† | NA | WHO, BM if MPN was suspected | 6/25 | 24 | 6/25 | 24 | 3/2/1/0/5 |
| DeStefano et al63 | 2007 | RC | 27/31 | NA | 48 (24-108)‡ | PVSG 2000 | 8/58 | 14 | 24/58 | 41 | 4/5/0/0/15 |
| McMahon et al50 | 2007 | RC | 9/1 | NA | NA | Not specified | 0/10 | 0 | 1/10 | 10 | 0/0/0/0/1 |
| Colaizzo et al21 | 2007 | RC | 44/55 | 41 (10-85) | 41 (3-114) | WHO 2001 | 9/99 | 9 | 17/99 | 17 | 3/5/5/2/5§ |
| Primignani et al52 | 2006 | RC | 29/44 | 42 (13-66) | NA | WHO 2001, based on BM only | 31/55 | 56 | 26/73 | 36 | 5/14/5/9/0 |
| Kocher et al55 | 2005 | RC | 10/10 | 51 (17-83) | 21 (2-61) | Not specified, BM if MPN was suspected | 6/20 | 30 | NA | NA | 2/4/0/0/0 |
| Janssen et al2 | 2001 | RC | NA | NA | 3.9 (0.1-13.1)† | Not specified, BM if MPN was suspected | 22/82 | 27 | NA | NA | 12/2/5/2/0§ |
| Denninger et al6 | 2000 | RC | NA | NA | NA | Not specified, BM if MPN was suspected | 5/36 | 14 | NA | NA | 5/0/0/6/0 |
| Valla et al12 | 1988 | RC | 14/17 | NA | NA | Not specified, BM if MPN was suspected | 7/31 | 23 | NA | NA | 2/1/2/6/0 |
RC indicates retrospective cohort; CC, case-control; U, unclassifiable; solitaryJAK2, solitary JAK2-positive; NA, not available; IQR, interquartile range; and BM, bone marrow biopsy.
MPNs that became overt during follow-up were included in subtype analysis.
Mean age/follow-up (range) was reported.
Median follow-up of patients with JAK2V617F-positive MPNs without elevated blood counts.
In each of these studies, also one patient with chronic myeloid leukemia was reported.